---
title: Brain stimulation reduces sleep fragmentation
nct_id: NCT06914466
status: RECRUITING
sponsor: Xuanwu Hospital, Beijing
study_type: OBSERVATIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT06914466"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06914466"
last_fetched: "2026-05-10T14:04:30.616Z"
source: "Parkinson's Pathways (curated)"
---
# Brain stimulation reduces sleep fragmentation

**Goal (in five words):** Brain stimulation reduces sleep fragmentation

**Official Title:** Neural Mechanisms and Clinical Applications of Deep Brain Stimulation for Modulating Sleep Dysregulation in Parkinson's Disease

**Trial ID:** [NCT06914466](https://clinicaltrials.gov/study/NCT06914466)

## Key Facts

- **Status:** RECRUITING
- **Study Type:** OBSERVATIONAL
- **Sponsor:** Xuanwu Hospital, Beijing
- **Target Enrollment:** 20 participants
- **Start Date:** 2024-09-01
- **Completion Date:** 2026-09-01
- **Conditions:** Deep Brain Stimulation, Parkinson's Disease and Parkinsonism, Sleep Disorder
- **Interventions:** Deep Brain Stimulation
- **Intervention Types:** PROCEDURE

## Summary For Families

The team wants to understand how stimulating the subthalamic nucleus can change the brain circuits that control sleep in Parkinson's, and whether specific stimulation patterns can reduce sleep fragmentation, REM sleep behavior problems, or daytime sleepiness. Using people who already have bilateral STN-DBS with the Medtronic Percept PC, researchers will compare sleep questionnaires, sleep studies, and the device's recorded brain signals to see which stimulation settings link to better sleep, STN-DBS delivers targeted electrical pulses that reshape overactive motor and nonmotor networks while the Percept records local field potentials to reveal neural activity behind sleep changes. They plan to enroll about 20 adults age 19 to 80 who had bilateral STN-DBS with the Percept PC and can complete follow-up, excluding those with other brain surgery, secondary Parkinsonism, other major nervous system diseases, severe medical or psychiatric illness, or major cognitive or communication barriers.

## Eligibility

- **Minimum age:** 19 Years
- **Maximum age:** 80 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

1. Diagnosis of Parkinson's disease: The diagnostic criteria for Parkinson's disease are the Clinical Diagnostic Criteria of UK PD Society Brain Bank Clinical Diagnostic Criteria or 2015 MDS Clinical Diagnostic Criteria for PD.All diagnoses of Parkinson's disease were made by three neurologists who were experienced in the field of movement disorders.
2. Patients who underwent bilateral STN-DBS(Medtronic Percept™ PC)
3. Patients who can cooperate with the completion of postoperative follow-up and clinical evaluation.

Exclusion Criteria:

1. Patients who underwent other brain surgery;
2. Other patients with secondary Parkinson's syndrome and Parkinsonism-plus syndrome;
3. Patients with other central nervous system and peripheral nervous system diseases;
4. Patients complicated with severe medical system diseases, or unable to tolerate clinical evaluation;
5. Patients with severe mental illness;
6. Patients who cannot complete informed consent due to cognitive and communication barriers, or refuse to sign informed consent.
```

## Locations (1)

- Xuanwu Hospital,Capital Medical University, Beijing, Beijing Municipality, China _(39.9075, 116.3972)_
  - Jiping Li, MD — (CONTACT) — 8610-83198899-8630 — yhljp89@163.com
  - Yuqing Zhang, MD — (PRINCIPAL_INVESTIGATOR)

## Central Contacts

- yuqing Zhang — (CONTACT) — 010-83922345 — yuqzhang@vip.163.com

---

*Canonical: https://parkinsonspathways.com/trial/NCT06914466*  
*HTML version: https://parkinsonspathways.com/trial/NCT06914466*  
*Source data: https://clinicaltrials.gov/study/NCT06914466*